ArticleFrontiers in oncology2025
Case Report: 3 cases of abdominal lesions with lower limb lymphedema-rare mutations in complex lymphatic anomalies.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complex lymphatic anomalies (CLAs) are rare vascular anomalies characterized by abnormal proliferation of lymphatic and blood vessels, often resulting in multisystem involvement with heterogeneous clinical manifestations. We present 3 patients with CLAs exhibiting overlapping features of lower limb lymphedema and intra-abdominal vascular malformations, a phenotypic combination infrequently described in literature. Circulating tumor DNA (ctDNA) analysis in 2 cases detected somatic mutations at significantly higher variant allele frequencies compared to population databases, and mutant genes that were previously rare in vascular diseases were reported. These noninvasive molecular findings demonstrate diagnostic utility in identifying novel genotype-phenotype associations, providing insights into disease mechanisms and informing therapeutic strategies for atypical CLAs presentations. Our observations highlight ctDNA as a promising tool for refining diagnosis and guiding personalized management in rare vascular anomalies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.